A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

By D. Blom, T. Hála, M. Bolognese, M. Lillestol, P. Toth, L. Burgess, R. Češka, E. Roth, M. Koren, Christie M. Ballantyne and 6 more. New England Journal of Medicine, 2014

699 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/8d480541d9ba40d0cf45fea465f3b42bfc2b2f19

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. A. Goldfine
2. W. Hiatt
3. Cecilia C. Low Wang
4. Connie N. Hess

In Surgery

1. J. Liao
2. A. Goldfine
3. W. Hiatt
4. Cecilia C. Low Wang
5. Connie N. Hess
6. Ulrich Laufs

Citations in the corpus

• CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016, background): “When added to maximal statin therapy, these once- or twice-monthly injectable agents reduce LDL-C by approximately 50%, raise HDL-C, and have favorable effects on other lipids (191-197).”
• Pleiotropic Effects of Statins on the Cardiovascular System (2017, background): “sin kexin 9 inhibitors (PCSK9i) that lower LDL-C levels by ≈60% alone and could be compared with a high-dose statin in terms of equivalency in LDL-C reduction.(71,72) High-dose”
• Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes – Mechanisms, Management, and Clinical Considerations (2016, positive): “Likewise, durability of evolocumab lowering of LDL cholesterol was sustained for 52 weeks in the study of patients with familial hypercholesterolemia or mixed hyperlipidemia either alone or added on to low versus high intensity statin therapy.(241) Additional beneficial effects on serum lipoproteins”